Peruzi-6.25 Davipharm tablets against hypertension, anti-angina (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Carvedilol

Ingredient

Composition information	Content
Carvedilol	6.25mg

Uses

indications

Peruzi 6.25 is indicated in the following cases:

Treatment of hypertension: The drug can be used alone or in combination with other drugs, especially with thiazide diuretics. Prove that by mortality, cardiovascular treatment time at the hospital, or it is necessary to adjust other heart failure drugs). Adrenergic.

Dynamic pharmacokinetics

absorption: Biological use of Carvedilol on average 20-25% because of incomplete absorption and because of its initial strong metabolism. After taking a dose of about 1-3 hours, the concentration in plasma is maximum. The concentration in plasma increases linearly to the dose, within the recommended dose range.

Distribution: The distribution volume is about 2 liters/ kg. Normal plasma clearance is about 500 ml/ min.

Metabolism: Three metabolites have a beta receptor blockage, but weak vascular dilatation effects. However, the concentration of these metabolites is low, and therefore does not contribute to the effect of the drug.

Elimination: Half lifetime elimination of Carvedilol is 6-7 hours after drinking. A small percentage of about 15% of oral dose is excreted through the kidney.

Before taking Peruzi-6.25 Davipharm tablets against hypertension, anti-angina (3 blisters x 10 tablets)

How to use

To reduce the potential of the risk of decrease in vertical blood pressure, carvedilol is recommended to drink with food. In addition, the manufacturer suggests that vasodilation manifestation in patients used at the same time the enzyme inhibitors can be reduced by taking Carvedilol 2 hours before taking the transferred enzyme inhibitor.

Dosage

Hypertension: The first dose of 12.5 mg, 1 time; increase to 25 mg after 2 days, drink once a day. Another way, the first dose of 6.25 mg oral twice a day, after 1 to 2 weeks increased to 12.5 mg, taken twice a day. If necessary, the dose may increase, apart at least 2 weeks apart, up to a maximum of 50 mg, 1 time, or divided into several doses. For the elderly, 12.5 mg oral 1 time can be effective.

Burgery: The first dose of 12.5 mg, taken 2 times a day; After 2 days increasing to 25 mg, 2 times a day.

heart failure: 3,125 mg oral 2 times a day for 2 weeks. After that, the dose may increase, if tolerated, up to 6.25 mg, taken 2 times a day. The dose may increase if tolerant, at least the next 2 weeks are recommended by 25 mg, taken twice a day, for patients weighing less than 85 kg or 50 mg, taken twice a day, for people weighing over 85 kg.

Before the start of Carvedilol therapy for congestive heart failure, patients are taking cardiac glycosides, diuretics, and/or enzyme inhibitors, must be stable with the dose of those drugs. The risk of loss of heart failure and/or decreased severe severe blood pressure in the first 30 days of treatment.

ILAND cardiomyopathy: 6.25 - 25 mg, taken 2 times a day.

Dosage adjustment in people with kidney failure: Unnecessary.

Dosage adjustment in people with liver failure: Contraindications

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose? The most common symptom of heart is hypotension and slow heart rate. Atrial block - ventricular, ventricular disorders in ventricular and heart stunning may occur at serious overdose, especially with membrane stabilizers (for example: propranolol). The impact on the central nervous system includes convulsions, coma and common respiratory extraction with propranolol and with tacit medicine in fat and other membrane inhibitors.

Therapy includes treatment of seizures, hypoglycemia, hyperkalemia and hypoglycemia. Slow heart rate and decreased blood pressure with atropine, isoproterenol, or with a pacemaker that can use glucagon. QRS is expanded due to a membrane stabilizer that can use superior bicarbonate sodium. For multi -dose activated carbon, hemorrhage can only help eliminate the blockage - beta with small distribution, with half a long life, or low internal clearance ( acebutolol , Atenolol, Nadolol, Sotalol).

What to do when forgetting a dose? Ignore the forgotten dose if it is close to the time for the next expected dose. Do not use more medicine to replace the forgotten dose.

Side Effects

When using Peruzi 6.25 , you may experience unwanted effects (ADR).

Common, ADR> 1/100

Body: headache , muscle aches, fatigue, shortness of breath.

circulating: dizziness, posture hypotension.

circulatory: Slow heart rate.

Blood: platelet increasing, leukopenia. Tears, irritation.

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Peruzi 6.25 contraindicated in the following cases:

Sound congestive heart failure (NYHA level III - IV) has not been treated with a standard regimen. Drugs.

Be cautious when using

Carvedilol caution must be used in patients with congital heart failure treated with digitalin, diuretics, or enzyme inhibitors that transfer angiotensin because of the co -effect that causes hypotension or/atrial - ventricular can be slowed.

Be careful in patients with diabetes with no or difficult to control, because beta receptor blockers can cover symptoms of blood glucose.

Must stop treatment when there is signs of liver damage.

Must be used carefully in people with peripheral artery diseases, people with anesthesia, people with contaminating syndrome.

If the patient does not tolerate other anti -hypertension drugs, caution can be used with very small doses of carvedilol for people with hypertension with bronchospasm.

Avoid stopping the drug suddenly, to stop the drug for 1-2 weeks.

Consider the risk of arrhythmia, if using carvedilol simultaneously with anesthetic smell. The risk must be considered if combined with carvedilol with anti -arrhythmia group I.

Not yet determined the safety and effectiveness of Carvedilol in children.

The ability to drive and operate machinery

No research on the effects of the drug on the ability to drive and operate machinery

Be careful when driving or operating machinery if the patient has a headache, dizziness when taking the drug, especially when starting treatment, changing medicine or using alcohol.

Pregnancy

Carvedilol has caused clinical damage in pregnancy. Only use this medication during pregnancy if the expected benefit is greater than the risk that may occur and as usual, not used in the last three months of pregnancy or almost giving birth.

Unwanted effects for fetuses such as slow heartbeat, lowering blood pressure, respiratory inhibition, reducing glucose - blood and reducing body temperature in infants can be used by pregnancy.

breastfeeding period

carvedilol can excrete in breast milk. The risk of unwanted effects in breastfeeding has not been seen.

Drug interaction

rifampicin may reduce carvedilol plasma concentrations by 70%.

The effect of other beta blockers decreases when combined with aluminum salts, barbiturates, calcium salts, cholestyramin, colestipol, non -selective blockers A1, penicillin (ampicilin), salicylate, and sulfnyrazon due to reduced biodiversity and plasma concentration.

Carvedilol can increase the effects of anti -diabetic drugs, calcium channel blockers, digoxin.

Carvedilol's interaction with clonidin can lead to an increase in blood pressure and reduce heart rate.

cimetidine increases the effects and bioavailability of carvedilol.

Other drugs that are capable of increasing the concentration and effects of carvedilol include quinidin, ﬂ uoxetin, paroxetin, and propafenon because these drugs inhibit CYP2D6.

Carvedilol increases the concentration of digoxin about 20% when taken at the same time.

Storage

In a dry place, avoid light, under 300C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.